See more : PT LCK Global Kedaton Tbk (LCKM.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Immuneering Corporation (IMRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Immuneering Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- NeoMagic Corporation (NMGC) Income Statement Analysis – Financial Results
- Sugi Holdings Co.,Ltd. (7649.T) Income Statement Analysis – Financial Results
- Industrial Bank Co., Ltd. (601166.SS) Income Statement Analysis – Financial Results
- Yield10 Bioscience, Inc. (YTEN) Income Statement Analysis – Financial Results
- Kavveri Telecom Products Limited (KAVVERITEL.BO) Income Statement Analysis – Financial Results
Immuneering Corporation (IMRX)
About Immuneering Corporation
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 316.95K | 2.08M | 2.31M | 1.92M |
| Cost of Revenue | 764.14K | 158.12K | 1.15M | 1.28M | 1.22M |
| Gross Profit | -764.14K | 158.83K | 926.89K | 1.03M | 696.74K |
| Gross Profit Ratio | 0.00% | 50.11% | 44.56% | 44.61% | 36.29% |
| Research & Development | 41.40M | 36.27M | 26.54M | 15.00M | 4.28M |
| General & Administrative | 16.76M | 15.61M | 8.27M | 3.11M | 2.71M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.76M | 15.61M | 8.27M | 3.11M | 2.71M |
| Other Expenses | 0.00 | 30.05K | -127.06K | 0.00 | 0.00 |
| Operating Expenses | 58.41M | 51.90M | 34.81M | 18.11M | 6.99M |
| Cost & Expenses | 58.41M | 52.06M | 35.97M | 19.39M | 8.21M |
| Interest Income | 3.61M | 1.01M | 169.90K | 42.66K | 57.66K |
| Interest Expense | 0.00 | 1.01M | 0.00 | 0.00 | 351.30K |
| Depreciation & Amortization | 352.08K | 796.79K | 159.07K | 79.31K | 18.08K |
| EBITDA | -58.06M | -51.47M | -33.68M | -17.00M | -7.34M |
| EBITDA Ratio | 0.00% | -16,316.29% | -1,629.17% | -733.74% | -382.35% |
| Operating Income | -58.41M | -51.74M | -33.89M | -17.08M | -6.29M |
| Operating Income Ratio | 0.00% | -16,325.77% | -1,629.17% | -739.01% | -327.71% |
| Total Other Income/Expenses | 4.94M | 1.23M | 42.84K | 42.66K | -1.42M |
| Income Before Tax | -53.47M | -50.51M | -33.84M | -17.04M | -7.71M |
| Income Before Tax Ratio | 0.00% | -15,937.29% | -1,627.11% | -737.17% | -401.59% |
| Income Tax Expense | 0.00 | -1.23M | -307.49K | -84.34K | 351.30K |
| Net Income | -53.47M | -49.28M | -33.54M | -17.04M | -8.06M |
| Net Income Ratio | 0.00% | -15,548.66% | -1,612.33% | -737.17% | -419.89% |
| EPS | -1.88 | -1.87 | -1.27 | -0.67 | -0.32 |
| EPS Diluted | -1.88 | -1.87 | -1.27 | -0.67 | -0.32 |
| Weighted Avg Shares Out | 28.42M | 26.39M | 26.32M | 25.51M | 25.51M |
| Weighted Avg Shares Out (Dil) | 28.42M | 26.39M | 26.32M | 25.51M | 25.51M |
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Piper Sandler 36th...
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
- Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients - - Granted FDA Orphan Drug Designation for IMM-1-104 in the Treatment of Pancreatic Cancer and Fast Track Designation...
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
The FDA bestows an orphan drug designation to Immuneering's lead candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares rise.
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study
Immuneering stock soars 41% as lead drug combo regimen shows superior initial efficacy in the first-line treatment of pancreatic cancer in a mid-stage study.
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
- Enrollment progressing well across all arms in the IMM-1-104 Phase 2a Trial, with Initial Data from Multiple Arms Expected in 2H 2024 - - Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer - - Preclinical Data...
Why is Immuneering (IMRX) Stock Up 24% Today?
Various names in the biotech sector are seeing big moves in today's session, as investors are clearly interested in rotation into a number of higher-growth small-cap stocks. Immuneering (NASDAQ: IMRX ) is certainly one such company generating outsized interest today.
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
- IMM-1-104 Fast Track designation now granted for the treatment of both first and second-line pancreatic ductal adenocarcinoma (PDAC); provides potential to accelerate IMM-1-104's path to U.S. FDA submission for PDAC - - Phase 2a trial of IMM-1-104 includes multiple...
3 Penny Stocks With 735% Average Upside, According to Wall Street
With the third quarter in full swing, the bulls have not lost their grip on equities.
Immuneering to Present at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the Jefferies Global Healthcare...
Source: https://incomestatements.info
Category: Stock Reports